Business Context and Reporting Period
This Form 8-K was filed by Dandrit Biotech USA, Inc. (the "Registrant") on January 12, 2018. The filing reports the entry into a Material Definitive Agreement, specifically an Agreement and Plan of Merger with Enochian Biopharma, Inc. ("Enochian"). The Registrant is a Delaware corporation, and the transaction involves a merger where a wholly-owned subsidiary of the Registrant will merge with Enochian, with Enochian surviving as the public entity.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins for the reporting period. However, it specifies a critical liquidity condition for the closing of the Merger:
- Cash Requirement: The Registrant must have not less than $19,000,000 in cash on hand at closing, less up to a maximum of $1,000,000 of expenses related to the Merger.
No data regarding debt levels or other financial statements is included in this specific filing.
Material Changes and Transaction Structure
The primary material change is the execution of the Merger Agreement. Key terms include:
- Consideration: Enochian stockholders will receive 50% of the Registrant's common stock issued and outstanding as of the effective time of the Merger. Additionally, they are entitled to earn-out shares pro rata upon the exercise or conversion of outstanding stock options and warrants.
- Intellectual Property: A condition of closing is the execution of a perpetual, royalty-free, exclusive worldwide license from the Majority Stockholder (Weird Science LLC) to the Company for HIV-related research, development, and commercialization.
- Corporate Governance: An Investor Rights Agreement grants the Majority Stockholder and RS Group (a significant Registrant stockholder) rights to nominate directors and consent to increases in the board size.
Guidance, Risks, and Conditions
The filing outlines several conditions precedent to the closing of the Merger, which represent key risks and contingencies:
- IP Due Diligence: The Registrant must be satisfied with all intellectual property due diligence of Enochian in its sole discretion.
- Financial Statements: Enochian must provide audited financial statements required for the Registrant's independent public accounting firm to prepare SEC-compliant filings.
- Lock-Up Provisions: A Standstill & Lock-Up Agreement restricts the Majority Stockholder and RS Group from selling half of their securities for 12 months and the other half for 24 months.
- Exclusivity: Both parties have covenanted not to solicit or negotiate with other parties regarding an acquisition during the interim period.
The filing does not contain forward-looking guidance on revenue or earnings projections.
Investor Verification Checklist
- Verify the Registrant's current cash balance to ensure it meets the $19,000,000 closing condition.
- Review the attached Merger Agreement (Exhibit 2.1) for specific details on the earn-out mechanism and stock option conversions.
- Confirm the status of the Intellectual Property license agreement (Exhibit 10.1) and the assignment of Study Results.
- Examine the Investor Rights Agreement (Exhibit 10.2) to understand the future composition of the Board of Directors.
- Check for the issuance of audited financial statements for Enochian as required for closing.